Introduction
Rapid recognition of esophageal intubation is important and can be achieved more promptly using carbon dioxide detection. 1 The new American Heart Association guidelines for intra-hospital resuscitation recommend the use of colorimetric carbon dioxide devices (CCDD) as a primary technique to confirm correct endotracheal tube placement. 2 Two brands commonly used are the Nellcor Pedi-Cap (Nellcor Puritan Bennett Inc., Pleasanton, CA, USA) and the Mini StatCO 2 (Mercury Medical, Clearwater, FL, USA). Exposure to CO 2 changes the color of an indicator from blue/purple (negative response) to yellow (positive response) indicating presence of CO 2 and implying correct placement of the endotracheal tube. Several factors are known to influence the ability of a CCDD to change colors: infants with poor cardiac function, inadequate ventilation or occluded airway may not exhale sufficient CO 2 to be detected by a CCDD. 3 Absence of circulation (cardiac arrest with inadequate CPR) may lead to false-negative responses of a CCDD due to the absence of gas exchange in the alveoli. 4 Our paper describes a previously unreported false-positive response of a CCDD. We report that epinephrine, when administered through an endotracheal tube may result in a color change.
Case A 38-week infant born with a congenital diaphragmatic hernia, pulmonary hypertension and critical lung hypoplasia was intubated in the delivery room and transported to the NICU. Upon arrival, the infant was electively reintubated for poor response to ventilation and suspected incorrect ETT placement (negative PediCap color change and poor breath sounds). The infant was then placed on high-frequency oscillatory ventilation (HFOV). Initial heart rate was in the 80s and transcutaneous O 2 saturations were in the 40s. The infant was removed from HFOV and received manual positive pressure ventilation (PPV). Initially, the Pedi-Cap during PPV remained purple. Direct visualization of the vocal cords was performed at this time and the ETT was visually confirmed to be in the trachea. The patient's heart rate decreased to the 50s with O 2 saturations in the 40s. The infant received a 0.1 mg dose of epinephrine via the ETT. The CCDD turned yellow for approximately 15 breaths then turned back to purple. The infant did not respond to the initial dose of epinephrine, and subsequently, received a second dose of epinephrine (again a color change to yellow for the CCDD was noted) with similar lack of clinical responses. The infant was placed back on HFOV. Shortly thereafter, the family decided to withdraw care and the infant expired.
Methods
To evaluate if the CCDD color change was secondary to the epinephrine provided via ETT, we analyzed the effect of several drugs commonly administered via ETT on two brands of CCDDs. Neonatal equivalent dosing of each drug was used with a test lung. 5 We evaluated all drugs using two different techniques. In the droplet exposure, each drug was applied directly onto the membrane of the CCDD and any color change was recorded. In the vapor exposure, each drug was administered into a neonatal size test lung followed by PPV through a CCDD (vapor exposure). In the vapor exposure, the resuscitation bag was attached to the test lung and compressed several times and any color change was recorded with each breath. A maximum of 15 breaths was used for each drug and CCDD. Vapor and droplet exposure experiments were repeated three times for each drug with identical results shown in the tables below. 'Yes' indicates a color change occurred; 'No' indicates no color change occurred.
Results
The results for the vapor and droplet exposures for each CCDD are presented in Tables 1 and 2 . Each experiment was repeated three times for each CCDD-drug combination and the results were always identical for the same combinations. While Epinephrine caused a false-positive response in the vapor exposure with the Nellcor Pedi-Cap, this was not found with the Mercury Mini StatCO 2 . For both CCDDs tested, epinephrine, atropine, infasurf and naloxone created false-positive responses in the droplet exposure experiments.
Discussion
While the American Academy of Pediatrics now recommends that epinephrine be given through an umbilical catheter, initial doses may still be given via the endotracheal tube. 6 We have shown that a false-positive color change in one commercially available CCDD can occur with the administration of epinephrine via the ETT and exposure of the device to drug vapor. Both commonly used devices showed a false-positive color change in response to droplet exposure to several medications (not related to pH), including epinephrine and surfactant. This may lead a provider to mistakenly assume correct ET tube placement.
In our case, a patient with severe pulmonary lung hypoplasia and ventilatory failure was found to have a color change on the CCDD. Even though the patient's ventilation was inadequate to cause a color change in the CCDD, for a brief period of time, we were lead to believe that ventilation was improved.
More concerning is the scenario, in which a patient is not properly intubated and epinephrine is given via the ETT into the esophagus. A false-positive color change response on the CCDD would lead the provider to mistakenly assume proper ETT placement. In this scenario, the time to diagnose the incorrect ETT placement may be delayed. Use of clinical indicators to determine esophageal intubation is slow, with an average time to recognition of 97 s. 7 Use of carbon dioxide detection has improved the time from esophageal intubation to detection with the potential for improved outcome. 1 In combination with endotracheal epinephrine, however, the CCDD may provide a false-positive result, which may lead to delayed recognition of esophageal intubation.
Conclusion
Our trial indicates that a false-positive CO 2 detection response can occur when epinephrine is instilled directly into the ETT. CCDDs have been shown to help in the detection of proper placement of the ETT and improve the time to recognition of an esophageal intubation. However, caution should be used when relying on a CCDD after the introduction (or instillation) of medications into the ETT, and other measures to confirm ETT position, including auscultation and other clinical assessment tools, should be emphasized. 
